Establishment Labs (NASDAQ:ESTA) Trading 7.9% Higher – Should You Buy?

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) were up 7.9% on Tuesday . The company traded as high as $45.72 and last traded at $46.28. Approximately 601,434 shares traded hands during trading, an increase of 46% from the average daily volume of 411,352 shares. The stock had previously closed at $42.88.

Wall Street Analyst Weigh In

Separately, Stephens reiterated an “overweight” rating and issued a $52.00 target price on shares of Establishment Labs in a research note on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $57.40.

Establishment Labs Stock Up 7.7 %

The company has a current ratio of 3.62, a quick ratio of 2.29 and a debt-to-equity ratio of 5.94. The company has a market capitalization of $1.29 billion, a price-to-earnings ratio of -17.91 and a beta of 1.12. The company has a 50-day moving average of $37.52 and a 200-day moving average of $41.34.

Establishment Labs (NASDAQ:ESTA) last released its earnings results on Wednesday, February 26th. The company reported ($0.98) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.34). Establishment Labs had a negative return on equity of 184.55% and a negative net margin of 46.13%. The company had revenue of $44.51 million during the quarter, compared to analyst estimates of $44.45 million. On average, equities analysts predict that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Establishment Labs

Several hedge funds have recently made changes to their positions in ESTA. Toronto Dominion Bank purchased a new stake in Establishment Labs in the fourth quarter valued at approximately $24,879,000. Brown Advisory Inc. raised its position in Establishment Labs by 23.1% during the fourth quarter. Brown Advisory Inc. now owns 2,338,369 shares of the company’s stock worth $107,729,000 after acquiring an additional 438,057 shares during the period. Capital Research Global Investors lifted its holdings in Establishment Labs by 29.3% during the fourth quarter. Capital Research Global Investors now owns 1,911,525 shares of the company’s stock valued at $88,064,000 after purchasing an additional 433,484 shares in the last quarter. Voya Investment Management LLC grew its position in shares of Establishment Labs by 7,249.5% in the fourth quarter. Voya Investment Management LLC now owns 408,262 shares of the company’s stock valued at $18,809,000 after purchasing an additional 402,707 shares during the period. Finally, Millennium Management LLC increased its stake in shares of Establishment Labs by 96.9% during the fourth quarter. Millennium Management LLC now owns 711,691 shares of the company’s stock worth $32,788,000 after purchasing an additional 350,213 shares in the last quarter. 72.91% of the stock is owned by institutional investors and hedge funds.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.